 |
|
|
| |
Effect of treatment of hepatitis B patients with tenofovir disoproxilor entecaviron risk of hepatocellular cancer and death in a U.S. cohort
|
| |
| |
Reported by Jules Levin
EASL 2019 April 14 Vienna
Stuart C. Gordon (sgordon3@hfhs.org)1, Yueren Zhou2 (yzhou1@hfhs.org), Jia Li (jli4@hfhs.org)2, Loralee B. Rupp (lrupp1@hfhs.org)3, Joseph A. Boscarino(jaboscarino@geisinger.edu)4, Yihe Daida(yihe.g.daida@kp.org)5, Mark A. Schmidt (mark.a.schmidt@kpchr.org)6, Sheri Trudeau (strudea1@hfhs.org)2, and Mei Lu (mlu1@hfhs.org)2, for the CHeCSInvestigators*
1Division of Gastroenterology and Hepatology, Henry Ford Health System and Wayne State University School of Medicine, DetroitMI; 2Department of Public Health Sciences, Henry Ford Health System, Detroit MI; 3Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit MI; 4Department of Epidemiology and Health Research, GeisingerClinic, Danville PA; 5Center for Health Research, Kaiser Permanente-Hawai'i, Waipahu HI; 6Center for Health Research, Kaiser Permanente-Northwest, Portland OR.
|
| |
|
|
|
|
|
